Osteocalcin-thymidine kinase gene therapy

N/A

Report date: 2023/10/26 16:41:03

Base Information

Drug NameOsteocalcin-thymidine kinase gene therapy
Drug Alias NameAd-OC-TKAd-OC-hsv-TK
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionThymidine phosphorylase stimulantsGene transference
TargetsThymidine phosphorylase
Therapy Area/IndicationsProstatic NeoplasmsBone Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive Companies +[1]  N/A
Active IndicationsN/A
Inactive IndicationsProstatic NeoplasmsBone Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A